Graft-versus-lymphoma effect after reduced intensity allogeneic hematopoietic stem cell transplantation from HLA-two loci mismatched father in a patient with refractory non-Hodgkin lymphoma.
A 10-year-old female developed a mediastinal mass and was diagnosed as mixed lineage lymphoblastic lymphoma. The tumor was extremely refractory, and she never achieved remission despite intensive therapy using 12 anti-lymphoma agents and local irradiation. She received reduced-intensity allogeneic peripheral blood stem cell transplantation from her HLA-two loci mismatched father, and achieved complete remission. However, the lymphoma relapsed four months later, and we abruptly discontinued immunosuppressive drugs. Concurrent with the development of grade III graft-versus-host disease, the lymphoma completely disappeared with an increase of activated T-cells in peripheral blood. The clinical course suggested the graft-versus-lymphoma effect against aggressive/refractory lymphoma.
Suminoe
Aiko
A
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Matsuzaki
Akinobu
A
Koga
Yuhki
Y
Hatano
Miho
M
Hara
Takuya
T
Hara
Toshiro
T
D002648:Child; D017809:Fatal Outcome; D005220:Fathers; D005260:Female; D006086:Graft vs Host Disease; D020350:Graft vs Tumor Effect / Q000276:immunology*; D006680:HLA Antigens / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D006680:HLA Antigens